Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Dinaciclib (SCH727965) - ≥98%, high purity , Cyclin-dependent kinase 9 inhibitor, CAS No.779353-01-4, Cyclin-dependent kinase 9 inhibitor

  • Moligand™
  • ≥98%
Item Number
D127362
Grouped product items
SKUSizeAvailabilityPrice Qty
D127362-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$88.90
D127362-25mg
25mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$400.90
D127362-100mg
100mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$652.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET

Novel, potent, selective cyclin-dependent kinase (CDK) inhibitor

View related series
cyclin dependent kinase 1 Inhibitor cyclin dependent kinase 2 Inhibitor cyclin dependent kinase 5 Inhibitor cyclin dependent kinase 9 Inhibitor

Basic Description

SynonymsDinaciclib|779353-01-4|SCH727965|Dinaciclib (SCH727965)|SCH 727965|SCH-727965|MK-7965|(S)-3-(((3-ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)pyridine 1-oxide|(2S)-1-[3-Ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]py
Specifications & Purity≥98%
Storage TempStore at -20°C
Shipped InDry ice
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionCyclin-dependent kinase 9 inhibitor
Product Description

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation.
A novel and potent cyclin-dependent kinase inhibitor for Cdk2, Cdk5, Cdk1, and Cdk9

Product Properties

ALogP1.9

Associated Targets

CDK1 Tchem Cyclin-dependent kinase 1 10 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK13 Tchem Cyclin-dependent kinase 13 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ERCC2 Tchem General transcription and DNA repair factor IIH helicase subunit XPD 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHD4 Tchem Chromodomain-helicase-DNA-binding protein 4 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK9 Tchem Cyclin-dependent kinase 9 11 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK8 Tchem Cyclin-dependent kinase 8 4 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK4 Tclin Cyclin-dependent kinase 4 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK2 Tchem Cyclin-dependent kinase 2 12 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK5 Tchem Cyclin-dependent-like kinase 5 10 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HSF1 Tchem Heat shock factor protein 1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKR1C3 Tchem Aldo-keto reductase family 1 member C3 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol
INCHI InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1
InChi Key PIMQWRZWLQKKBJ-SFHVURJKSA-N
Canonical SMILES CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCCC4CCO
Isomeric SMILES CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO
PubChem CID 46926350
Molecular Weight 396.49

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot NumberCertificate TypeDateItem
L2325080Certificate of AnalysisJan 02, 2024 D127362
D1727044Certificate of AnalysisNov 16, 2022 D127362

Chemical and Physical Properties

SolubilityDMSO: ≥ 56 mg/mL
Melt Point(°C)107-111°C

Safety and Hazards(GHS)

Pictogram(s) GHS08,   GHS07
Signal Danger
Hazard Statements

H315:Causes skin irritation

H319:Causes serious eye irritation

H372:Causes damage to organs through prolonged or repeated exposure

H340:May cause genetic defects

Precautionary Statements

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352:IF ON SKIN: wash with plenty of water.

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P281:Use personal protective equipment as required.

P270:Do not eat, drink or smoke when using this product.

P362+P364:Take off contaminated clothing and wash it before reuse.

P203:Obtain, read and follow all safety instructions before use.

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P318:if exposed or concerned, get medical advice.

P337+P317:If eye irritation persists: Get medical help.

P332+P317:If skin irritation occurs: Get medical help.

P319:Get medical help if you feel unwell.

Related Documents

 SDS

 Specification Sheet

References

1. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al..  (2010)  The landscape of somatic copy-number alteration across human cancers..  Nature,  463  (7283): (899-905).  [PMID:20164920]
2. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M.  (2010)  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma..  Cancer Cell,  18  (1): (63-73).  [PMID:20609353]
3. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES.  (2012)  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors..  Cell Cycle,  11  (14): (2756-61).  [PMID:22767154]
4. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H et al..  (2012)  The requirement for cyclin D function in tumor maintenance..  Cancer Cell,  22  (4): (438-51).  [PMID:23079655]
5. Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, Genesca L, Trimarchi T, Kelliher MA, Clark M et al..  (2012)  Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia..  Cancer Cell,  22  (4): (452-65).  [PMID:23079656]
6. Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH.  (2013)  A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS..  Cancer Biol Ther,  14  (7): (597-605).  [PMID:23792647]
7. Martin MP, Olesen SH, Georg GI, Schönbrunn E.  (2013)  Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains..  ACS Chem Biol,  8  (11): (2360-5).  [PMID:24007471]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.